Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cell Injection Targeting CD19/CD70 (CHT105) in Patients With Relapsed/Refractory Autoimmune Diseases

NCT07811622 is registered in ClinicalTrials.gov with Nanjing Miracle Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07811622
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07811622 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Cell Injection Targeting CD19/CD70 (CHT105) in Patients With Relapsed/Refractory Autoimmune Diseases
Lead sponsor
Nanjing Miracle Biotechnology Co., Ltd.
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
December 31, 2027
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia (itp)